iRhythm Holdings, Inc. (FRA:I25)
Germany · Delayed Price · Currency is EUR | Market Cap | 3.24B -11.2% |
| Revenue (ttm) | 683.30M +27.4% |
| Net Income | -24.10M |
| EPS | -0.75 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 339.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 97.50 |
| Previous Close | 97.00 |
| Day's Range | 97.50 - 97.50 |
| 52-Week Range | 87.50 - 179.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About iRhythm Holdings
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that ... [Read more]
Financial Performance
In 2025, iRhythm Holdings's revenue was $747.14 million, an increase of 26.24% compared to the previous year's $591.84 million. Losses were -$44.55 million, -60.67% less than in 2024.
Financial numbers in USD Financial StatementsNews
iRhythm initiated with an Overweight at Stephens
Stephens initiated coverage of iRhythm (IRTC) with an Overweight rating and $160 price target iRhythm specializes in remote cardiac monitoring and arrhythmia detection and its Zio platform has been ra...
iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026
SAN FRANCISCO, July 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent di...
iRhythm price target lowered to $160 from $174 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on iRhythm (IRTC) to $160 from $174 and keeps a Buy rating on the shares as part of a broader research…
iRhythm removed from Conviction List at William Blair
William Blair removed iRhythm (IRTC) from the firm’s Conviction List citing the expiration of the six month time horizon. There is no change in William Blair’s investment thesis, and its…
iRhythm price target lowered to $150 from $160 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on iRhythm (IRTC) to $150 from $160 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
iRhythm Holdings Transcript: Truist Securities MedTech Conference 2026
A recent cybersecurity incident was contained without operational or financial impact, and regulatory timelines remain intact. Zio MCT's FDA submission is on track for a first half 2027 launch, with a new mobile gateway and significant AI-driven efficiency gains expected. Innovative channel partners are driving the fastest revenue growth, and regulatory remediation efforts are progressing.
iRhythm discloses cyber incident, says no impact on device systems, patient safety
iRhythm Holdings on Monday reported unauthorized activity involving data maintained on some third-party applications last week, but said it has not identified any impact on products, patient safety ...
iRhythm Holdings Transcript: 46th Annual William Blair Growth Stock Conference
Cardiac monitoring market share continues to grow, driven by product innovation, primary care expansion, and international opportunities. FDA clearance of a third-generation algorithm and strong Q1 financials support raised guidance and long-term margin goals.
iRhythm Holdings Slides: 46th Annual William Blair Growth Stock Conference
iRhythm Holdings has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
iRhythm price target lowered to $152 from $180 at Canaccord
Canaccord lowered the firm’s price target on iRhythm (IRTC) to $152 from $180 and keeps a Buy rating on the shares. The firm updated its modelto correct an error in…
iRhythm Holdings Transcript: AGM 2026
The meeting covered director elections, approval of the 2026 Equity Incentive Plan, amendments to governance documents, auditor ratification, and executive compensation. All proposals passed, and stockholder questions will be addressed post-meeting.
iRhythm Holdings to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict dise...
iRhythm price target lowered to $180 from $225 at BofA
BofA lowered the firm’s price target on iRhythm (IRTC) to $180 from $225 and keeps a Buy rating on the shares. After having hosted 34 medtech companies last week in…
iRhythm Holdings Transcript: Bank of America Global Healthcare Conference 2026
LCD updates expanded patient access and Q1 delivered strong revenue and margin growth, led by Zio Monitor and innovative channels. AI-driven efficiencies and new product launches are expected to drive further margin gains, while international and innovative channel expansion remain key growth areas.
iRhythm price target raised to $157 from $155 at Citi
Citi raised the firm’s price target on iRhythm (IRTC) to $157 from $155 and keeps a Buy rating on the shares.
iRhythm price target raised to $174 from $170 at Truist
Truist raised the firm’s price target on iRhythm (IRTC) to $174 from $170 and keeps a Buy rating on the shares. The company delivered another strong revenue and EBITDA beat…
iRhythm price target raised to $175 from $166 at Baird
Baird raised the firm’s price target on iRhythm (IRTC) to $175 from $166 and keeps an Outperform rating on the shares. The firm updated its model following beat and raise…
iRhythm price target lowered to $175 from $215 at JPMorgan
JPMorgan lowered the firm’s price target on iRhythm (IRTC) to $175 from $215 and keeps an Overweight rating on the shares.
iRhythm price target lowered to $185 from $225 at Oppenheimer
Oppenheimer lowered the firm’s price target on iRhythm (IRTC) to $185 from $225 and keeps an Outperform rating on the shares following quarterly results. The firm notes there were no…
iRhythm price target lowered to $160 from $170 at Evercore ISI
Evercore ISI lowered the firm’s price target on iRhythm (IRTC) to $160 from $170 and keeps an Outperform rating on the shares.
iRhythm price target raised to $255 from $254 at Needham
Needham raised the firm’s price target on iRhythm (IRTC) to $255 from $254 and keeps a Buy rating on the shares after its Q1 earnings beat. The company continues to…
iRhythm price target lowered to $180 from $198 at Canaccord
Canaccord lowered the firm’s price target on iRhythm (IRTC) to $180 from $198 and keeps a Buy rating on the shares. The firm said they delivered a solid Q1 with…
iRhythm Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 25.7% revenue growth, margin expansion, and improved profitability, driven by strong volume across core and emerging channels. Guidance for 2026 was raised, with continued investment in AI, workflow integration, and international growth.
iRhythm Holdings Earnings release: Q1 2026
iRhythm Holdings released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.